Anal Bioanal Chem
Analytical and Bioanalytical Chemistry
1618-2642
1618-2650
Springer-Verlag
Berlin/Heidelberg


2045123
17849102
1559
10.1007/s00216-007-1559-6
Original Paper


A new highly specific and robust yeast androgen bioassay for the detection of agonists and antagonists

Bovee
Toine F. H.

+31-317-475598
+31-317-417717
toine.bovee@wur.nl

1

Helsdingen
Richard J. R.

1

Hamers
Astrid R. M.

1

van Duursen
Majorie B. M.

2

Nielen
Michel W. F.

1

Hoogenboom
Ron L. A. P.

1

1
RIKILT, Institute of Food Safety, Wageningen University and Research Center, P. O. Box 230, 6700 AE Wageningen, The Netherlands 
2
IRAS, Institute for Risk Assessment Sciences, Utrecht University, P. O. Box 80177, 3508 TD Utrecht, The Netherlands 

12
9
2007

11
2007

389
5
1549
1558
27
4
2007

3
7
2007

15
8
2007


© Springer-Verlag 2007

β
50
50
β
50
α
β
-boldenone are 2.3, 1.4, and 0.15 respectively. The results presented in this paper demonstrate that this new yeast androgen bioassay is fast, sensitive, and very specific and also suited to detect compounds that have an antiandrogenic mode of action.

Keywords
Antagonists
Brominated flame retardants
Crosstalk
Metabolism
Receptor
Saccharomyces cerevisiae


issue-copyright-statement
© Springer-Verlag 2007




Introduction
1
2
3
4
5
6
].
7
8
9
]. This feature is very helpful in detecting both known and unknown compounds.
10
11
13
14
16
17
19
20
22
].
β
β
β
-galactosidase as a reporter protein.

Materials and methods
Chemicals
23
α
β
β
α
α
β
β
β
-galactosidase assay kit was from Pierce Biotechnology (Rockford, IL, USA). 2,4,6-Tribromophenol (TBP), BDE-39, and the hydroxyl derivative 4-OH-BDE-17 were synthesized at the Wallenberg Laboratory (Stockholm University, Sweden).

Yeast strains
Saccharomyces cerevisiae
URA3
−

HIS3
−

LEU
−

β
-galactosidase as a marker was kindly provided by D.P. McDonnell (Duke University, USA).

Plasmids
CYC1
 yeast expression vectors were obtained from the American Type Culture Collection (ATCC, Rockville, Maryland, USA). The pyEGFP3 plasmid was a gift from A.J. Brown (Stanford University, USA).

Construction of the p403-GPD-hAR expression vector
Xba
Bam
Xba
Bam
HI restriction site.
Xba
Bam
HI and ligated into the corresponding site of the p403-GPD yeast vector. Plasmid digestion and PCR controls revealed several good clones.

2
CYC1
-yEGFP reporter vector
Sac
Msc
AGAACA
TGTTCT
AGAACA
TGTTCT
AGAACA
TGTTCT
AGAACA
TGTTCT
GACTTTAGCT-3′.
CYC1
24
Hind
Sal
Hind
Sal
2
CYC1
 reporter construct. Plasmid digestion and PCR controls revealed several good clones.

Transformation of yeast cells
−
−
−
23
2
CYC1
Stu
URA3
l
l
Nsi
HIS3
2
CYC1
-yEGFP reporter and the p403-GPD-hAR expression construct.

PCR controls
2

CYC1
CYC1
 terminator. The sequence of the 5′-primer was 5′-TCTATAGACACACAAACACAA-3′ and the sequence of the 3′-primer was 5′-GGGAGGGCGTGAATGTAAG-3′. PCR III was performed with the primers that were also used to obtain the full length cDNA of the hAR (see “Construction of the p403-GPD-hAR expression vector”).

Streamlined yEGFP assay with the yeast androgen bioassay
β
\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$y = {a_{0} } \mathord{\left/ {\vphantom {{a_{0} } {{\left[ {1 + {\left( {x \mathord{\left/ {\vphantom {x {a_{1} }}} \right. \kern-\nulldelimiterspace} {a_{1} }} \right)}^{{a_{2} }} } \right]}}}} \right. \kern-\nulldelimiterspace} {{\left[ {1 + {\left( {x \mathord{\left/ {\vphantom {x {a_{1} }}} \right. \kern-\nulldelimiterspace} {a_{1} }} \right)}^{{a_{2} }} } \right]}}$$\end{document}

\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$
{\text{response}} = {{\text{maximum response}} - {\text{minumum response}}} \mathord{\left/
 {\vphantom {{{\text{maximum response}} - {\text{minumum response}}} {{\left[ {1 + {\left( {{{\left[ {agonist} \right]}} \mathord{\left/
 {\vphantom {{{\left[ {agonist} \right]}} {EC_{{50}} }}} \right.
 \kern-\nulldelimiterspace} {EC_{{50}} }} \right)}^{{width{\text{ }}of{\text{ }}transition}} } \right]}}}} \right.
 \kern-\nulldelimiterspace} {{\left[ {1 + {\left( {{{\left[ {agonist} \right]}} \mathord{\left/
 {\vphantom {{{\left[ {agonist} \right]}} {EC_{{50}} }}} \right.
 \kern-\nulldelimiterspace} {EC_{{50}} }} \right)}^{{width{\text{ }}of{\text{ }}transition}} } \right]}}
$$\end{document}

50
 is the concentration of the test compound giving half-maximum response.

lacZ
β
-galactosidase assay
4
β
β
o
β
d
β
d
o
o
-nitrophenol is measured in a Biotek (Winooski, VT, USA) model ELx 808 series ultra microplate reader at 405 nm. Densities of the yeast culture were determined by measuring the OD at 630 nm. The measured response at 405 nm was corrected for the OD at 630 nm.


Results and discussion
CYC1
URA3
Sac
Msc
CYC1
Xho
Sph
CYC1
23
HIS3
β
lacZ
-based yeast androgen bioassay provided by McDonnell. In addition, the antiandrogenic properties of several brominated flame retardants were investigated.
PCR controls
1
1
2
2
CYC1
CYC1
1
CYC1
CYC1
CYC1
CYC1
CYC1
CYC
1
2
CYC1
Fig. 1
a
2
2
CYC1
CYC1
CYC1
CYC1
CYC1
b
yEGFP
 yeast enhanced green fluorescent protein





Dose–response curves obtained with the new yeast androgen bioassay
2
α
β
β
α
β
β
β
β
β
25
26
27
β
Fig. 2
β
α
β
β
17β-T
β
DHT
α
Prog
Dex
17β-E2
β
Bold
β
-boldenone




1
50
50
β
50
α
β
β
β
β
α
α
β
Table 1
50
RAP
) of compounds in the yeast androgen biosensor expressing yeast enhanced green fluorescent protein in response to androgens

Compound
a

b

50
c

d



β
-Testosterone 
Positive (11/11)
Strong AR agonist
76
1.0

α
-Dihydrotestosterone
Positive (21/21)
Strong AR agonist, weak ER agonist
33
2.3

β
-Boldenone


510
0.15

β
-Trenbolone
Positive
Binds strongly to AR
52
1.5

Methyltrienolone
Positive (8/8)
AR agonist
54
1.4

Tetrahydrogestrinone

AR agonist
65
1.2

β
-Estradiol
Positive (10/11)
AR agonist and antagonist, strong ER agonist
9,000
0.0084

Estrone
Positive (2/2)
AR agonist, strong ER agonist
NR
NR

α
-Estradiol
Negative (1/1)
ER agonist
NR
NR

α
-Ethynylestradiol
Negative (1/1)
Strong ER agonist
NR
NR

Diethylstilbestrol
Negative (2/2)
Strong ER agonist
NR
NR

e

Negative (1/1)
ER antagonist
NR
NR

f

Positive (7/9)

1,700
0.045

Medroxyprogesterone acetate 
Positive (4/4)
Weak AR agonist
1,500
0.051

Corticosterone
Negative (1/1)
Binds weakly to AR
NR
NR

Dexamethasone
Positive (3/4)
AR agonist
NR
NR

Flutamide
Negative (5/5)
AR antagonist
NR
NR

2,4,6-Tribromophenol 


NR
NR

BDE-19


NR
NR

4-OH-BDE-17


NR
NR



AR
ER
NR
 no response
a
27
])
b
27
]
c
50
 is the concentration giving half-maximum response.
d
50
β
50
 of the compound.
e
This compound was toxic to yeast above 30 μM.
f
β
-testosterone. The maxima obtained with 4-androstenedione and progesterone are about 40 and 35%, respectively.



27
27
β
β
β
10
β
28
]. Dexamethasone was also described as an androgen receptor agonist in the NIH publication, showing androgenic activity in three out of four mammalian assays, but gave a negative result in our yeast androgen bioassay. However, these MCRG systems use an MMTV-Luc reporter construct or an ARE-Luc reporter construct. Both the MMTV and the ARE sequence are recognized by the glucocorticoid receptor and this means that the response found in these MCRG systems is probably due to crosstalk, as the glucocorticoid receptor is normally expressed in all cell types.

lacZ
-based yeast androgen bioassay
3
lacZ
2
50
50
29
lacZ
50
α
50
lacZ
α
lacZ
β
lacZ
lacZ
lacZ
30
lacZ
lacZ
50
15
β
50
31
Fig. 3
β
α
β
β
lacZ
-based yeast androgen bioassay: β-galactosidase assay.” Signals are the mean of a triplicate with the SD



Table 2
50
 concentrations and RAPs of compounds in the yeast androgen bioassay expressing β-galactosidase in response to androgens

Compound
50
a
29
]
50
b
 in our laboratory
RAP


β
-Testosterone
4.7
11.5
1.0

α
-Dihydrotestosterone
3.5
4.9
2.3

β
-Boldenone
ND
70
0.2

β
-Trenbolone
ND
13
0.9

Methyltrienolone
ND
3.7
3.1

Tetrahydrogestrinone
ND
11.5
1.0

β
-Estradiol 
86.1
95
0.1

α
-Estradiol
ND
NR
NR

Progesterone
89.3
170
0.068

Corticosterone
ND
NR
NR

Dexamethasone
ND
NR
NR



ND
 not determined
a
29
], using the McDonnell yeast androgen bioassay
b
lacZ
-based yeast androgen bioassay”)




Antiandrogenic activity
4
α
1
4
α
50
32
Fig. 4
α
α
α
TBP
 2,4,6-tribromophenol






Conclusions
A recombinant yeast cell was constructed that expresses the hAR and yEGFP as a reporter protein in response to androgens. Compared with other yeast androgen bioassays, this new biosassay showed a similar limit of detection and dynamic range. However, the measurement of the fluorescence (yEGFP) can be followed as a function of incubation time and is easier, quicker, and cheaper than the measurement of the β-galactosidase or the luciferase activity, which needs cell wall disruption and/or the addition of expensive substrates. Owing to the ease of the yEGFP measurement, standard deviations are generally less than 3%. Moreover, the assay seems to be more robust and more specific for detecting compounds with a pure androgenic mode of action.
α
-dihydrotestosterone, the most potent endogenous androgen, demonstrating that this yeast androgen bioassay is suited to detect compounds with both agonistic and antagonistic characteristics.
α
16
33
34
]. Future work will include the validation of the assay for urine and feed and the screening of prohormones with and without metabolic activation. To mimic the in vivo metabolic activation, liver slices, liver cell lines, liver S9 enzymes, and pure enzymes will be used.


Acknowledgement
This project was supported financially by the Dutch Ministry of Agriculture, Nature and Food Quality.

References
1.
Pike
MC

Spicer
DV

Dahmoush
L

Press
MF


Epidemiol Rev
1993
15
17
35

8405201


2.
Skakkebæk
NE

Jørgensen
N

Main
KM

Rajpert-DeMeyts
E

Leffers
H

Andersson
A

Juul
A

Carlsen
E

Mortensen
GK

Jensen
TK

Toppari
J


Int J Androl
2006
29
2
11
10.1111/j.1365-2605.2005.00573.x

16466518


3.
Jobling
S

Reynolds
T

White
R

Parker
MG

Sumpter
JP


Environ Health Perspect
1995
103
582
587
10.2307/3432434

7556011


4.
Jenkins
RL

Wilson
EM

Angus
RA

Howell
WM

Kirk
M


Toxicol Sci
2003
73
53
59
10.1093/toxsci/kfg042

12700410


5.
Lemaire
G

Terouanne
B

Mauvais
P

Michel
S

Rahmani
R


Toxicol Appl Pharmacol
2004
196
235
246
10.1016/j.taap.2003.12.011

15081270


6.
Henley DV, Lipson N, Korach KS, Bloch CA (2007) N Engl J Med 356:479–485

7.
Garcia-Reyero
N

Grau
E

Castillo
M

Lopez De Alda
MJ

Barcelo
D

Pina
B


Environ Toxicol Chem
2001
20
1152
1158
10.1897/1551-5028(2001)020<1152:MOEDIS>2.0.CO;2

11392124


8.
Mueller
SO


J Chromatogr B
2002
777
155
165
10.1016/S1570-0232(02)00282-9

Mueller SO (2002) J Chromatogr B 777:155–165 

9.
Sonneveld
E

Riteco
JAC

Jansen
HJ

Pieterse
B

Brouwer
A

Schoonen
WG

Burg
B


Toxicol Sci
2006
89
173
187
10.1093/toxsci/kfj009

16221957


10.
Hoogenboom
LAP

Haan
L

Hooijerink
D

Bor
G

Murk
AJ

Brouwer
A


Acta Pathol Microbiol Immunol Scand
2001
109
101
107

Hoogenboom LAP, De Haan L, Hooijerink D, Bor G, Murk AJ, Brouwer A (2001) Acta Pathol Microbiol Immunol Scand 109:101–107 

11.
Graumann
K

Breithofer
A

Jungbauer
A


Sci Total Environ
1999
225
69
79
10.1016/S0048-9697(99)80018-7

10028704


12.
Witters
HE

Vangenechten
C

Berckmans
P


Water Sci Technol
2001
43
117
123

11380169


13.
Dhooge
W

Arijs
K

D’Haese
I

Stuyvaert
S

Versonnen
B

Janssen
C

Verstaete
W

Comhaire
F


Anal Bioanal Chem
2006
386
1419
1428
10.1007/s00216-006-0669-x

16896612


14.
Rehmann
K

Schramm
K

Kettrup
AA


Chemosphere
1999
38
3303
3312
10.1016/S0045-6535(98)00562-1

10390844


15.
Michelini
E

Leskinen
P

Virta
M

Karp
M

Roda
A


Biosens Bioelectron
2005
20
2261
2267
10.1016/j.bios.2004.10.018

15797324


16.
Bovee
TFH

Bor
G

Heskamp
HH

Hoogenboom
LAP

Nielen
MWF


Food Addit Contam
2006
23
556
568
10.1080/02652030600557163

16766455


17.
Haelens
A

Verrijdt
G

Callewaert
L

Christiaens
V

Schauwaers
K

Peeters
B

Rombauts
W

Claessens
F


Biochemistry
2003
369
141
151
10.1042/BJ20020912

Haelens A, Verrijdt G, Callewaert L, Christiaens V, Schauwaers K, Peeters B, Rombauts W, Claessens F (2003) Biochemistry 369:141–151 

18.
Shaffer
PL

Jivan
A

Dollins
DE

Cleassens
F

Gewirth
DT


Proc Natl Acad Sci USA
2004
101
4758
4763
10.1073/pnas.0401123101

15037741


19.
Brodie
J

McEwan
IJ


J Mol Endocrinol
2005
34
603
615
10.1677/jme.1.01723

15956332


20.
Schoonen
WG

Deckers
G

Gooyer
ME

Ries
R

Kloosterboer
HJ


J Steroid Biochem Mol Biol
2000
74
213
222
10.1016/S0960-0760(00)00125-4

11162927


21.
Blankvoort
BMG

Groene
EM

Meeteren-Kreikamp
AP

Witkamp
RF

Rodenburg
RJT

Aarts
JMMJG


Anal Biochem
2001
298
93
102
10.1006/abio.2001.5352

11673900


22.
Willemsen
P

Scippo
M

Maghuin-Rogister
G

Martial
JA

Muller
M


Anal Bioanal Chem
2005
382
894
905
10.1007/s00216-005-3253-x

15906006


23.
Bovee
TFH

Helsdingen
JR

Koks
PD

Kuiper
HA

Hoogenboom
LAP

Keijer
J


Gene
2004
325
187
200
10.1016/j.gene.2003.10.015

14697524


24.
Cormack
BP

Bertram
G

Egerton
M

Gow
NAR

Falkow
S

Brown
AJP


Microbiology
1997
143
303
311

9043107


25.
Fuhrman
U

Krattenmacher
R

Slater
EP

Fritzmeier
KH


Contraception
1996
54
243
251
10.1016/S0010-7824(96)00195-3

8922878


26.
Collins
DC


Am J Obstet Gynecol
1994
170
1508
1513

8178899


27.
NIH (2003) NIH publication no 03-4503

28.
Bovee
TFH

Helsdingen
JR

Rietjens
IMCM

Keijer
J

Hoogenboom
LAP


J Steroid Biochem Mol Biol
2004
91
99
109
10.1016/j.jsbmb.2004.03.118

15276617


29.
Gaido
KW

Leonard
LS

Lovell
S

Gould
JC

Babaï
D

Portier
CJ

McDonnell
DP


Toxicol Appl Pharmacol
1997
143
205
212
10.1006/taap.1996.8069

9073609


30.
Imhof
MO

McDonnell
DP


Mol Cell Biol
1996
16
2594
2605

8649367


31.
Lee
HJ

Lee
YS

Kwon
HB

Lee
K


In Vitro Toxicol
2003
17
237
244
10.1016/S0887-2333(03)00009-2

Lee HJ, Lee YS, Kwon HB, Lee K (2003) In Vitro Toxicol 17:237–244 

32.
Hamers
T

Kamstra
JH

Sonneveld
E

Murk
AJ

Kester
MHA

Andersson
PL

Legler
J

Brouwer
A


Toxicol Sci
2006
92
157
173
10.1093/toxsci/kfj187

16601080


33.
Nielen
MWF

Bovee
TFH

Engelen
MC

Rutgers
P

Hamers
ARM

Rhijn
JA

Hoogenboom
LAP


Anal Chem
2006
78
424
431
10.1021/ac051317q

16408923


34.
Rijk J, Groot M, Peijnenburg A, Bovee T, Van Engelen M, Nielen M (2006) Paper presented at the 5th international symposium on hormone and veterinary drug residue analysis, Antwerp, Belgium




